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miR-378a-3p modulates tamoxifen 
sensitivity in breast cancer MCF-7 
cells through targeting GOLT1A
Kazuhiro Ikeda1, Kuniko Horie-Inoue1, Toshihide Ueno2, Takashi Suzuki3, Wataru Sato1, 
Takashi Shigekawa4, Akihiko Osaki4, Toshiaki Saeki4, Eugene Berezikov5, Hiroyuki Mano2 & 
Satoshi Inoue1,6
Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using 
aromatase inhibitors or anti-estrogens such as tamoxifen. A majority of breast cancer, however, will 
often fail to respond to endocrine therapy. In the present study, we explored miRNAs associated with 
endocrine therapy resistance in breast cancer. High-throughput miRNA sequencing was performed 
using RNAs prepared from breast cancer MCF-7 cells and their derivative clones as endocrine therapy 
resistant cell models, including tamoxifen-resistant (TamR) and long-term estrogen-deprived 
(LTED) MCF-7 cells. Notably, miR-21 was the most abundantly expressed miRNA in MCF-7 cells and 
overexpressed in TamR and LTED cells. We found that miR-378a-3p expression was downregulated in 
TamR and LTED cells as well as in clinical breast cancer tissues. Additionally, lower expression levels 
of miR-378a-3p were associated with poor prognosis for tamoxifen-treated patients with breast 
cancer. GOLT1A was selected as one of the miR-378a-3p candidate target genes by in silico analysis. 
GOLT1A was overexpressed in breast cancer specimens and GOLT1A-specific siRNAs inhibited the 
growth of TamR cells. Low GOLT1A levels were correlated with better survival in patients with breast 
cancer. These results suggest that miR-378a-3p-dependent GOLT1A expression contributes to the 
mechanisms underlying breast cancer endocrine resistance.
Estrogen is an important endocrine hormone that regulates the growth and differentiation of the nor-
mal mammary gland1,2. The hormone also plays a critical role in the development and progression of 
breast cancer, which is one of the most common cancers among women1,2. The estrogen receptor α 
(ERα ) is a member of the nuclear receptor superfamily that functions as transcription factors3–5. ERα 
mediates various functions of estrogen in its normal and malignant target tissues, including breast can-
cer3–5. Determination of ERα status is clinically used as a prognostic and predictive factor in the man-
agement of breast cancer. Approximately 85% of breast cancers are ERα positive and can be treated 
with endocrine therapy using anti-estrogens such as tamoxifen or aromatase inhibitors6–8. Tamoxifen 
has been used for years for adjuvant treatment, which significantly reduces the risk of recurrence of 
breast cancer9. Despite the obvious benefits of tamoxifen, approximately 40% of patients with early-stage 
breast cancer treated with tamoxifen as adjuvant therapy would eventually suffer from the relapse with 
tamoxifen-resistant disease10. Thus, studies have been performed to elucidate the molecular mechanisms 
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underlying endocrine resistance; however, only several potential targets and signaling pathways have 
been revealed11–13. Therfore, a better understanding of the tamoxifen-resistant mechanism may provide 
novel strategies to overcome tamoxifen resistance in breast cancer.
MicroRNAs (miRNAs) are small noncoding RNAs consisting of an average of 22 nucleotides. miRNAs 
can function as post-transcriptional regulators by binding to 3′ -untranslated regions (3′ -UTRs) of their 
target mRNAs in sequences that have imperfect or perfect complementarity, repressing the translation or 
degradation of their target mRNAs14,15. Nowadays, particular attention has been paid to the deregulation 
of miRNAs in tumor progression and metastasis as one of the new transcriptional regulators involved 
in cancer biology16–18. While the molecular mechanisms underlying tamoxifen resistance in terms of its 
key regulators and signaling events remain to be elucidated, miRNAs could be novel therapeutic targets 
for endocrine therapy resistant cancers.
Several studies have recently reported the role of miRNAs in tamoxifen resistance. These studies provide 
a list of miRNAs potentially involved in tamoxifen resistance, including miR-87319, miRNAs-221/22220–22, 
miR-519a23, miR-126 and miR-10a24, miRNA-200b and miR-200c25, miR-146a, -27a, -145, -21, -155, 
-15a, -125b, and let-7s26,27, miR-37528, miR-45129, miR-34230, and miR-574-3p31. For example, miR-873 
is downregulated in tamoxifen-resistant MCF-7 cells and in breast cancer tissues compared with normal 
tissue. miR-873 decreases ER transcriptional activity through the modulation of ERα phosphorylation 
and inhibits the proliferation of breast cancer cells via targeting cyclin-dependent kinase 3 (CDK3)19. 
Loss of miR-375 expression is reported in tamoxifen-resistant breast cancer cells derived from long-term 
passage of MCF-7 cells with tamoxifen28. Re-expression of miR-375 sensitized tamoxifen-resistant breast 
cancer cells to tamoxifen and partly reversed the epithelial-mesenchymal transition (EMT)-like proper-
ties. This report showed that MTDH, which encodes metadherin, is a direct target of miR-37528. miR-
574-3p has been identified as a tamoxifen response-related miRNAs in breast cancer cells by miRNA 
library-based functional screening31. miR-574-3p potentially targets clathrin heavy chain (CLTC) whose 
expression is associated with tamoxifen sensitivity in tamoxifen-resistant breast cancer cells.
In the present study, we performed high-throughput sequencing of miRNAs in human breast cancer 
MCF-7 cells and its derivative tamoxifen-resistant TamR cells and long-term estrogen-deprived (LTED) 
cells. Differentially expressed miRNAs were identified by comparing miRNA expression profiles among 
those cells. miR-21 was determined as an upregulated miRNA in TamR and LTED cells, and let-7s (let-7a 
and f) and miR-378a-3p were identified as downregulated ones. We further studied the expression of 
miR-378a-3p in clinical breast cancer specimens and found that the miRNA was downregulated in can-
cer tissues compared to adjacent normal tissues. Additionally, lower miR-378a-3p expression levels were 
associated with poor prognosis for tamoxifen-treated patients with breast cancer. By in silico analysis 
and luciferase reporter assay for miRNA binding sites, golgi transport 1A (GOLT1A) was identified as 
a candidate miR-378a-3p target. Loss-of-function experiments for GOLT1A in TamR cells resulted in 
a decrease of tamoxifen-resistant cell growth. Low GOLT1A levels were also shown to be correlated 
with better survival in patients with breast cancer. These results show that miR-378a-3p and its target 
GOLT1A can provide new insights into the signaling pathways associated with tamoxifen resistance in 
breast cancer and could be applied to the development of alternative diagnostic and therapeutic options 
for advanced breast cancer.
Results
Identification of miRNAs differentially expressed in breast cancer cells and endocrine thera-
py-resistant cells using high throughput sequencing. To identify novel miRNAs associated with 
endocrine therapy-resistance of breast cancer cells, tamoxifen-resistant (TamR) cells32 were obtained 
from MCF-7 cells by long-term (> 3 months) culture with 1 μ M tamoxifen and long-term estrogen-de-
prived (LTED) cells33 were established from MCF-7 cells by culturing them in phenol red-free Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% dextran-charcoal stripped fetal bovine serum 
(dcc FBS). High-throughput miRNA sequencing was performed using RNAs prepared from parental 
MCF-7, TamR and LTED cells. Mapping of small RNA reads on the human genome (NCBI35 assembly) 
and prediction of novel miRNAs were performed as described previously34. An average of 4.6 million 
reads per sample was mapped on miRNAs. To compare miRNA expression profiles of these cells, a 
read count for each miRNA was shown as a frequency against the total mapped read count per sample. 
miRNAs exhibiting > 10 reads were selected and resulted in a list of 94 annotated miRNAs in MCF-7, 
TamR, and LTED cells (Supplementary Table 1). No confident novel miRNA was predicted from the 
data. Among these annotated miRNAs, 9 and 20 miRNAs were upregulated (> 1.2-fold) in TamR and 
LTED cells, respectively, compared with parental MCF-7 cells. Fifty five miRNAs were downregulated 
(< 0.7-fold) in both TamR and LTED cells compared with their parental cells. Two and 37 miRNAs were 
commonly upregulated and downregulated, respectively, in TamR and LTED cells compared with their 
parental cells (Fig. 1a). We found that the percentages of miR-21 counts were approximately two-third of 
the total counts for 94 miRNAs in MCF-7 cells and > 75% of the total counts in TamR and LTED cells 
(Fig. 1b). miR-21 is a known onco-miRNA in cancer, and its overexpression is shown to be associated 
with advanced clinical stage, lymph node metastasis, and poor prognosis in cancer patients, including 
breast cancer patients35–39. It has been also shown that miR-21 regulates the expression of target genes, 
including phosphatase and tensin homolog (PTEN), programmed cell death 4 (PDCD4), and tropomy-
osin 1 (TPM1) in breast cancer cells40–42.
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Figure 1. miRNA expression profiles of breast cancer MCF-7 and its derivative endocrine therapy 
resistant cells. (a) Differentially expressed miRNAs in tamoxifen-resistant breast cancer cells (TamR) and 
long-term estrogen-deprived breast cancer cells (LTED) compared to their parental MCF-7 cells. TamR 
and LTED were established from MCF-7 cells (see Materials and Methods). Small RNA libraries were 
constructed from MCF-7, TamR, and LTED cells and sequenced using the Illumina GAIIx. (b) Percentages 
of top 20 miRNAs abundantly expressed in MCF-7 and endocrine therapy resistant cells. Percentages in 
distinctive cell lines were determined by a read count for each indicated miRNA normalized to the total 
count of 94 selected miRNAs (> 10 reads) listed in Supplementary Table S1.
www.nature.com/scientificreports/
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Let-7f and let-7a, members of let-7 family, were also identified as abundantly and differentially 
expressed miRNAs among these cells. The expression levels of both let-7f and let-7a were decreased in 
TamR and LTED cells compared with those in MCF-7 cells. Let-7 family miRNAs have been generally 
considered as tumor suppressor miRNAs and the expressions of let-7 family members were reported 
to be downregulated in many cancer types including breast cancer and at times during tumor progres-
sion43,44. Let-7a and let-7f expression was inversely correlated with that of LIN28, which inhibits the 
biogenesis of the let-7 family and is shown to contribute to breast tumorigenesis45,46.
miR-378a-3p was another abundantly and differentially expressed miRNAs among these cells, as its 
expression in TamR and LTED cells was downregulated compared with that in MCF-7 cells. miR-378a-3p 
may contribute to the pathophysiology of cancers, which might be suggested by some studies in colorec-
tal cancer and rhabdomyosarcoma47,48. We further studied miR-378a-3p because its functional role has 
not been yet elucidated in breast cancer.
Knockdown of miR-378a-3p reverses tamoxifen-dependent suppression of cell growth in 
MCF-7 cells. To validate the endogenous expression levels of miR-21-5p, let-7f-5p, and miR-378a-3p, 
we performed quantitative polymerase chain reaction (qPCR) using cDNAs reversely transcribed from 
the RNAs prepared from MCF-7, TamR, and LTED cells (Fig. 2a). miR-21 expression levels were signifi-
cantly upregulated, whereas those of let-7f and miR-378a-3p were significantly downregulated in TamR, 
and LTED cells compared with MCF-7 cells. To further assess the functional role of miR-378a-3p in the 
proliferation of breast cancer cells, we performed loss-of-function studies using the miRNA inhibitor, 
anti-miR-378a-3p. The expression of miR-378a-3p was significantly reduced in MCF-7 cells transfected 
with anti-miR-378a-3p (Fig.  2b). A cell viability assay showed that tamoxifen treatment significantly 
repressed the growth of MCF-7 cells transfected with a control miRNA inhibitor. When the cells were 
transfected with anti-miR-378a-3p, however, tamoxifen-mediated suppression of cell growth was impaired 
in MCF-7 cells (Fig. 2c). On the other hand, overexpression of miR-378a-3p reduced tamoxifen-resistant 
growth of TamR cells (Supplementary Fig. S1). These results indicate that miR-378a-3p downregulation 
will contribute to tamoxifen resistance in breast cancer cells. To assess the downregulation mechanism of 
miR-378a-3p in TamR cells, we investigated the effect of 5-aza-2′ -deoxycytidine (5Aza-dC), an inhibitor 
of DNA methylation, on the expression of miR-378a-3p (Supplementary Fig. S2). We observed that the 
expression of miR-378a-3p was increased by the treatment with 5-Aza-dC. Notably, in parental MCF-7 
cells, 5Aza-dC was not influential on the expression levels of miR-378a-3p, suggesting that the epige-
netic regulation of miR-378a-3p expression would be accompanied with acquired tamoxifen resistance 
(Supplementary Fig. S3).
Decreased miR-378a-3p expression in clinical breast cancer tissues is associated with poor 
prognosis. miR-378a-3p expression levels were examined in clinical breast cancer samples and adja-
cent normal tissues (Fig.  3a). miR-378a-3p expression was significantly lower in breast cancer tissues 
than in adjacent normal tissues. Moreover, we assessed the association between miR-378a-3p levels 
and clinical outcomes using a breast cancer cohort with previously reported miRNA microarray data 
deposited in the Gene Expression Omnibus (GEO) database (GSE37405)(Fig.  3b). This dataset con-
tains the miRNA expression data of 152 ER-positive primary breast cancers from high-risk patients. 
All patients had received adjuvant tamoxifen therapy as a monotherapy (median clinical follow-up: 4.6 
years) and the half of the patients had developed distant recurrence (median time-to-recurrence: 3.5 
years)49. Using the data of 109 patients out of 152 patients for whom miR-378a-3p expression data were 
available, Kaplan-Meier analysis was performed to evaluate survival (time to recurrence) for groups with 
high and low expression of miR-378a-3p. Kaplan-Meier survival analysis indicates that patients with low 
miR-378a-3p levels presented poor recurrence-free survival (log-rank, P = 0.012) (Fig.  3b). The results 
indicate that miR-378a-3p downregulation could be correlated with the development and progression of 
tamoxifen resistance in breast cancer.
Identification of candidate target genes for miR-378a-3p. To identify miR-378a-3p candidate 
targets, we used 2 target gene prediction programs, TargetScan50 and miRanda51 (Fig. 4a). TargetScan and 
miRanda identified 97 and 1,159 candidate targets for miR-378a-3p, respectively. Notably, 95 genes were 
common between these programs. Of these candidates, we focused on GOLT1A because it presented one 
of the highest precision score. To examine whether miR-378a-3p directly regulates GOLT1A expression, 
we transfected MCF-7 cells with pre-miR-378a-3p for 48 h and then evaluated GOLT1A mRNA expression 
by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Transfection with pre-miR-
378a-3p significantly decreased GOLT1A mRNA expression level in MCF-7 cells compared to that of the 
control pre-miR (Fig. 4b). We next constructed luciferase reporter vectors containing either the wild-type 
GOLT1A 3′ -UTR sequence with a putative binding site for miR-378a-3p or the altered sequences of the 
3′ -UTR in which the putative binding site was mutated (mutations 1 and 2) (Fig. 4c). In 293T cells, the 
luciferase assay demonstrated that miR-378a-3p decreased the activity of luciferase reporter with the 
wild-type sequence, but not that of the reporters with the mutated sequences (Fig. 4d). This result sug-
gests that miR-378a-3p regulates GOLT1A expression by binding to the 3′ -UTR of GOLT1A.
www.nature.com/scientificreports/
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GOLT1A knockdown restores tamoxifen sensitivity and low GOLT1A levels are associated 
with better survival in patients with breast cancer. Since GOLT1A was shown as a candidate 
miR-378a-3p target in breast cancer cells, we investigated whether a negative correlation between miR-
378a-3p and GOLT1A expression can be observed in clinical breast cancer specimens (Fig. 5a). A neg-
ative correlation was shown between the expression levels of miR-378a-3p and GOLT1A (r = − 0.32, 
P < 0.05). To examine a functional role of GOLT1A in the tamoxifen response, we performed a 
loss-of-function study in TamR cells using GOLT1A siRNA. We found that GOLT1A mRNA expression 
was markedly repressed in TamR cells transfected with GOLT1A siRNA (Fig.  5b). Cell proliferation 
assay showed a significant growth inhibition of cells transfected with GOLT1A siRNA as compared to 
the control transfectants (Fig.  5c). It was confirmed by using another siRNA (siGOLT1A-2) that the 
growth inhibitory effect of GOLT1A silencing was observed markedly when TamR cells were treated 
with tamoxifen (Supplementary Fig. S4). To further examine whether the tumor-suppressive effect of 
miR-378a-3p is mediated by GOLT1A, MCF-7 cells were transfected with the combinations of anti-miR-
378a-3p and siGOLT1A (Supplementary Fig. S5). Anti-miR-378a-3p transfection upregulated the MCF-7 
Figure 2. miR-21, let-7f, and miR-378a-3p expression determined by qPCR and effect of miR-378a-3p 
knockdown on MCF-7 cell growth in the presence of tamoxifen. (a) miR-21, let-7f, and miR-378a-3p 
expression levels in MCF-7, TamR, and LTED cells were determined by qPCR and normalized to RNU48 
levels. Data are presented as mean ± SD. Statistical analysis was performed using the Mann-Whitney U 
test. **P < 0.01. (b) Knockdown efficiency of anti-miR-378a-3p. MCF-7 cells were transfected with anti-
miR-378a-3p or negative control for 48 h. miR-378a-3p levels were determined by qPCR and normalized to 
RNU48 levels. Data are presented as mean ± SD in triplicates; **P < 0.01. (c) Knockdown of miR-378a-3p 
significantly increased MCF-7 cell growth in the presence of tamoxifen. Cells were transfected with anti-
miR-378a-3p or negative control for 12 h, and then treated with 1 μ M tamoxifen or vehicle. Cell viability was 
analyzed using the WST-8 cell proliferation assay at 1, 3, and 5 days after transfection. Data are presented as 
mean ± SD, in triplicate; *P < 0.05.
www.nature.com/scientificreports/
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cell growth in the presence of tamoxifen compared with anti-miR negative control transfection; however, 
the tamoxifen-resistant growth induced by anti-miR-378a-3p was abrogated by siGOLT1A. We then 
examined the Oncomine microarray database to determine whether GOLT1A expression was altered 
in other cohorts of clinical breast cancer samples52. Two datasets indicated that GOLT1A was substan-
tially overexpressed (by > 2-fold) in clinical breast cancers compared to normal breast tissues (P < 1e-8, 
Fig. 5d). Of note, we found that low GOLT1A expression was associated with good prognosis for breast 
cancer in a breast cancer microarray dataset (Fig. 5e). These results suggest that GOLT1A plays a role in 
malignant alteration of breast cancer, including the acquisition of tamoxifen resistance.
Discussion
In the present study, we identified miRNAs that are differentially expressed in endocrine therapy resistant 
breast cancer cells (TamR and LTED) compared to parental MCF-7 cells. Among them, miR-21 and let-7 
(let-7f and let-7a) that are generally known as an onco-miRNA and an anti-onco-miRNA, respectively, 
were the top three differentially expressed miRNAs in the endocrine therapy resistant breast cancer cells. 
miR-21 and let-7s (let-7f and let-7a) expression levels are increased and decreased, respectively, in the 
endocrine therapy resistant breast cancer cells, suggesting their roles that will contribute to aggressive 
type of breast cancer, including the acquisition of tamoxifen resistance35,43.
As the fourth most differentially expressed miRNA in the endocrine therapy resistant breast cancer 
cells, we focused on miR-378a-3p whose expression levels were decreased in these cells. miR-378a-3p 
knockdown facilitated MCF-7 cell growth in the presence of tamoxifen. In addition, miR-378a-3p expres-
sion was reduced in clinical breast cancer tissues compared with cancer-surrounding normal tissues and 
low expression of miR-378a-3p was associated with poor prognosis in ER-positive breast cancer patients 
treated with adjuvant tamoxifen. In a clinicopathological study of colorectal cancer, miR-378a-3p expres-
sion is decreased in cancer tissues compared to that in adjacent normal colorectal tissues47. miR-378a-3p 
expression was correlated with pathological parameters, including histological differentiation and TNM 
stage, and low miR-378a-3p expression was significantly associated with shorter survival time. Ectopic 
miR-378a-3p expression could inhibit colorectal cancer cell growth and colony formation and induce 
apoptosis and cell cycle arrest. Loss- and gain-of-function experiments of miR-378a-3p in colorectal can-
cer cells suggest that miR-378a-3p may regulate the expression of the insulin-like growth factor 1 recep-
tor (IGF1R) as a target gene. A significant negative correlation between IGF1R protein and miR-378a-3p 
expression levels was observed in colorectal cancer tissues. In another study, miR-378a-3p downregula-
tion is observed in rhabdomyosarcoma tissues and cell lines48. miR-378a-3p overexpression suppressed 
IGF1R expression in rhabdomyosarcoma-derived RH30 cells and decreased the phosphorylation level of 
Figure 3. Reduced expression of miR-378a-3p in clinical breast cancer tissues is associated with 
poor prognosis for tamoxifen-treated patients. (a) Decreased miR-378a-3p expression levels in breast 
cancer tissues compared with those in paired adjacent normal tissues. miR-378a-3p expression levels were 
determined by qPCR and normalized to RNU48 levels. **P < 0.01. (b) Kaplan-Meier survival analysis 
according to miR-378a-3p levels in tamoxifen-treated breast cancer patients. The recurrence free survival of 
miR-378a-3p high-expressing group (n = 74) was significantly lower than that of the low-expressing group 
(n = 35; log-rank test; P = 0.012).
www.nature.com/scientificreports/
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Figure 4. Identification of miR-378a-3p target genes in breast cancer (a) Schematic presentation of 
miR-378a-3p target prediction by in silico analyses. Venn diagrams indicating numbers of candidate hits 
determined by the TargetScan and miRanda prediction algorithms. Candidate genes commonly predicted by 
the algorithms are described. (b) Overexpression of miR-378a-3p suppressed GOLT1A mRNA expression. 
MCF-7 cells were transfected with pre-miR-378a-3p or control miR for 48 h and the expression levels of 
miR-378a-3p and GOLT1A mRNA were then evaluated by qPCR and qRT-PCR, respectively. Data are 
presented as mean ± SD; *P < 0.05; **P < 0.01. (c) Location of putative miR-378a-3p-binding sequence in 
the 3′ -UTR of GOLT1A gene and its mutated sequences in luciferase reporters. (d) Luciferase reporter assay 
using vectors containing a putative GOLT1A 3′ -UTR binding site for miR-378a-3p and mutated versions of 
the site. MCF-7 cells were transiently transfected with psiCHECK2 vectors containing either the wild-type or 
mutated putative binding sites for miR-574-3p, together with pre-miR-378a-3p precursor or control pre-miR 
for 48 h. The luciferase assay was then performed. Data are presented as mean ± SD; **P < 0.01.
www.nature.com/scientificreports/
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AKT protein, which is known as a key signaling molecule in rhabdomyosarcoma. miR-378a-3p overex-
pression resulted in an increase of apoptosis and a decrease of cell growth in RH30 cells. miR-378a-3p 
could also induce myogenic differentiation by modulating myogenic marker genes in RH30 cells. In this 
report, treatment with the DNA methyltransferase inhibitor, 5-Aza-dC, upregulated miR-378a-3p expres-
sion. These findings together with our data suggest that miR-378a-3p may play a tumor-suppressive role 
in malignant tumors. In breast cancer, we assumed that miR-378a-3p downregulation may particularly 
Figure 5. GOLT1A knockdown restored tamoxifen resistance and low GOLT1A levels correlate with 
better survival in patients with breast cancer. (a) Negative correlation between miR-378a-3p and GOLT1A 
expression levels in breast cancer tissues. The expression levels of miR-378a-3p and GOLT1A mRNA were 
examined in cancer samples used in Fig. 3a. (b) Knockdown efficiency of GOLT1A siRNA. TamR cells 
were transfected with siGOLT1A or negative control for 48 h. GOLT1A mRNA levels were determined by 
qRT-PCR and normalized to GAPDH levels. Data are presented as mean ± SD, in triplicate; **P < 0.01. 
(c) GOLT1A knockdown significantly reduced TamR cell growth in the presence of tamoxifen. Cells were 
transfected with siGOLT1A or negative control. Cell viability was then analyzed by WST-8 cell proliferation 
assay at 1, 3, and 5 days after transfection. Data are presented as mean ± SD, in triplicate; *P < 0.05. (d) 
GOLT1A mRNA was overexpressed in clinical breast cancer tissues compared to normal mammary tissues, 
based on the Oncomine cancer profiling database, by > 2-fold at P < 1e-8. (e) GOLT1A expression correlates 
with poor relapse-free survival in patients with breast cancer. Survival curves for high (n = 42) and low 
(n = 117) expression groups dichotomized at the optimal cut point are plotted using the PrognoScan64. The 
95% confidence intervals for each group are also indicated by dotted lines.
www.nature.com/scientificreports/
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contribute to the acquisition of endocrine therapy resistance. Epigenetic modification may lead to the 
deregulation of miR-378a-3p expression in breast cancer cells53,54.
We selected GOLT1A as one of the miR-378a-3p candidate target genes by in silico algorithms. 
Our computational analysis is consistent with our experimental results that GOLT1A mRNA level was 
downregulated in MCF-7 cells transfected with miR-378a-3p precursor. Luciferase reporter assay using 
the 3′ -UTR region of GOLT1A gene including a putative binding site for miR-378a-3p suggested that 
miR-378a-3p could decrease GOLT1A mRNA expression. In addition, GOLT1A knockdown by siRNA 
restored tamoxifen sensitivity in TamR cells. Moreover, the examination of publicly available microarray 
datasets revealed that high levels of GOLT1A expression correlated with poor rates of survival for patients 
with breast cancer. These results suggest that miR-378a-3p and its candidate target gene, GOLT1A, could 
contribute to the mechanisms underlying the endocrine resistance of breast cancer.
GOLT1A is an evolutionarily conserved protein with a structure including four putative transmem-
brane domains. Got1p has been identified as a yeast homolog of GOLT1A by screening for mutations 
that show synthetic lethality with a membrane protein sft2, which is localized in the Golgi appara-
tus55. The yeast study showed that Got1p protein is present in the early Golgi cisternae. Got1p mutant 
yeast exhibited reduced endoplasmic reticulum (ER)-to-Golgi transport due to the impairment of 
SNARE-dependent fusion. Another yeast study revealed that Got1p displayed moderate suppressor activ-
ity toward temperature-sensitive mutations in the SEC23 and SEC31 genes, which encode subunits of the 
coat protein complex II (COPII), a type of vesicle coat protein that transports forward from the rough 
ER to the Golgi apparatus56. The study further showed that Got1p was efficiently packaged into COPII 
vesicles and cycled rapidly between the ER and Golgi compartments. As overexpression of yeast Got1p 
or N-terminal region of human GOLT1A rather impaired the ER-to-Golgi transport56,57, GOLT1A could 
plausibly saturate or somehow interfere the normal cargo recongnition functions of the COPII vesicles. 
Further studies will be required to fully assess the role of GOLT1A in the ER-to-Golgi network with 
differential expression levels, nevertheless, GOLT1A could influence membrane properties and modulate 
vesicle formation in the ER-to-Golgi network.
Recent evidence suggests that the ER-to-Golgi network regulates cellular processes including stress 
response, apoptosis, and mitotic checkpoint in cancer cells. In prostate cancer, Golgi is emerging as a new 
therapeutic target since several Golgi-associated molecules have been demonstrated to be regulated by 
androgen58. Brefeldin A (BFA) is known as is an inhibitor of ER-to-Golgi protein transport by inhibiting 
the interaction between ADP-ribosylation factor 1 (Arf1) and guanine nucleotide exchange factor (GEF). 
Treatment of mammalian cells with BFA induces both ER and Golgi stress due to its ability to cause a 
cytotoxic accumulation of proteins in the ER that would normally be trafficked through the Golgi to be 
processed for secretion. The stress to both organelles resulting from BFA treatment can induce apop-
tosis59,60. The inhibition of the Arf1-GEF interaction will be beneficial for cancer therapy. For example, 
limited effective therapeutic options are available for patients with chronic lymphocytic leukemia (CLL) 
refractory to alkylating agents such as fludarabine61. It is notable that BFA could induce apoptosis in 
primary CLL cells from fludarabine-refractory patients61. Although BFA and its derivatives have not 
progressed beyond the pre-clinical stage of drug development because of their poor bioavailability, tar-
geting the ER-to-Golgi network will be an attractive therapeutic option for cancers, especially for those 
that respond poorly to conventional treatments. It remains to be investigated whether new inhibitors for 
the ER-to-Golgi network can manage tamoxifen-resistant breast cancers, particularly those with high 
expression of GOLT1A and with altered ER-to-Golgi network.
In summary, we have identified miR-378a-3p as a modulating factor for the tamoxifen response in 
breast cancer by high throughput sequencing. A combination of in silico and in vitro analyses indicates 
that GOLT1A is a potential target of miR-378a-3p. These findings could be applied to develop alternative 
approaches to breast cancer diagnosis and treatment.
Methods
Cell culture. MCF-7 and 293T cells were purchased from ATCC (Manassas, VA, USA) and cultured 
in Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 
units/ml penicillin, and 50 μ g/ml streptomycin at 37 °C in a humidified atmosphere of 5% CO2 in air. 
Resistant clones for tamoxifen (TamR) were established from MCF-7 cells by long-term (> 3 months) 
culture with 1 μ M tamoxifen32. Tamoxifen was purchased from Sigma (St. Louis, MO, USA). Long-term 
estrogen-deprived (LTED) cells were established from MCF-7 cells by culturing them in phenol red-free 
DMEM supplemented with 10% dextran-charcoal stripped FBS (dccFBS).
RNA extraction and high-throughput sequencing. Total RNA was isolated from MCF-7, TamR 
and LTED cells using the ISOGEN reagent (Nippon Gene, Toyama, Japan) in accordance with the manu-
facturer’s instructions. Small RNA cDNA library was generated from the total RNAs and high-throughput 
sequencing was performed using an Illumina GAIIx sequencer (Illumina, San Diego, CA, USA)62. 
Mapping of small RNA reads on human genomes (NCBI35 assembly) and prediction of novel miRNAs 
were performed as describes previously34.
Transfection of miRNA precursors/inhibitors and siRNA. Pre-miR-378a-3p and its positive control 
as well as anti-miR-378a-3p and its negative control were purchased from Ambion (Carlsbad, CA, USA). 
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Transfection of miRNA precursors or inhibitors was carried out using Lipofectamine RNAiMAX transfec-
tion reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instruction. siRNA duplexes, 
siGOLT1A (5′ -GAUUCUUCAGCCUCUUUAAGG-3′ and 5′ -UUAAAGAGGCUGAAGAAUCCG-3′ ) 
and siGOLT1A-2 (5′ -GAAACCUACGGAUUCUUCA-3′ and 5′ -UGAAGAAUCCGUAGGUUUCCA-3′ ) 
both of which target GOLT1A was synthesized using an algorithm that significantly improves the target 
specificity of siRNA, in particular, by efficiently estimating off-target sequences63. A non-targeting con-
trol siRNA (siControl) with no homology to known gene targets in mammalian cells was obtained from 
RNAi Inc. (Tokyo, Japan)63. Cells were cultured overnight and transfected with siRNA at a final concen-
tration of 10 nM using Lipofectamine RNAiMAX. Knockdown efficiency of siRNA was determined by 
qRT-PCR using RNA prepared from the cells 48 h after transfection and normalized to that of siControl.
qPCR and qRT-PCR. Total RNA was extracted from cells or tissues using the ISOGEN reagent. For 
treatment of 5-aza-2′ -deoxycytidine (5-Aza-dC), cells were incubated with 1 or 10 μ M 5-Aza-dC or 
vehicle for 72 h. miRNA levels were determined by qPCR using triplicate TaqMan microRNA assays 
(Applied Biosystems, CA, USA). The target gene mRNA levels were evaluated by the StepOne Real-time 
PCR System (Applied Biosystems) using cDNAs converted from total RNA with SuperScript III Reverse 
Transcriptase (Invitrogen). Results from 3 independent experiments were normalized to the expression 
of endogenous RNU48 for miRNA or that of GAPDH for mRNA, respectively. Primers for GOLT1A and 
GAPDH were as follows: GOLT1A forward: 5′ - GGGCCTGTCCCTCATCATT -3′ ,
GOLT1A reverse: 5′ - TTTGTGCCGTTGGAAGAAGAA -3′ ,
GAPDH forward: 5′ -GGTGGTCTCCTCTGACTTCAACA-3′ , and
GAPDH reverse: 5′ -GTGGTCGTTGAGGGCAATG-3′ .
miRNA target prediction. Candidate targeted genes by miR-378a-3p were examined using 2 online 
database algorithms for miRNA target prediction: TargetScan (http://www.targetscan.org/) and miRanda 
(http://www.microrna.org/microrna/getGeneForm.do)50,51.
Cell growth assay. Cell proliferation was evaluated using the WST-8 assay kit (Nacalai Tesque, Kyoto, 
Japan). Two thousands of MCF-7 or TamR cells per well were cultured in 96-well plates and 10 μ L of 
WST-8 solution was added to each well at the indicated time points after transfection. Cells were fur-
ther incubated for 2 h at 37 °C in a 5% CO2 incubator. The absorbance was measured at 450 nm with 
Multiscan FC Microplate Photometer (Thermo Fisher Scientific, Rochester, NY, USA).
Luciferase reporter assay. The sequence of GOLT1A 3′ -UTR containing a putative binding site for 
miR-378a-3p was amplified by specific primers using MCF-7 cDNA and inserted into the psiCHECK-2 
vector (Promega, Madison, WI, USA). Two mutants for the putative binding site for miR-378a-3p were 
constructed by PCR with the mutated primers. For 3′ -UTR luciferase assay, 293T cells were transfected 
with psiCHECK2 vector containing the wild-type or mutated putative binding sites for miR-378a-3p 
together with pre-miR-378a-3p precursor or control pre-miR using Lipofectamine 2000 transfection 
reagent (Invitrogen). The psiCHECK2 empty vector was also transfected as a mock control. Luciferase 
reporter assay was performed using the Dual-Luciferase Reporter Assay System (Promega) 48 hours after 
transfection. Firefly luciferase activities for GOLT1A 3-UTR reporters were normalized to those for cor-
responding Renilla luciferase activities. Experiments were performed in triplicate, and the results were 
expressed as mean ± SD.
Clinical specimens. All clinical breast cancer tissues (n = 40) and the adjacent normal tissues (n = 16) 
were resected from patients those received surgery at Saitama Medical University. All procedures were 
performed under a protocol approved by the institutional Ethics Committee, and written informed con-
sent was obtained from all patients. The methods were carried out in accordance with the approved 
guidelines. Total RNA was isolated from these dissected samples and subjected to qPCR and qRT-PCR 
analyses. Oncomine Research Edition46 was used for the evaluation of GOLT1A mRNA expression in 
clinical breast cancer and normal mammary tissues based on microarray datasets. Kaplan–Meier curves 
of relapse-free survival times stratifying breast cancer patients by GOLT1A expression were obtained 
using the Prognoscan (http://www.abren.net/PrognoScan/), which is a database for meta-analysis of the 
prognostic value of genes64.
We also used the publicly available dataset GSE3740549 from the Gene Expression Omnibus reposi-
tory (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc = GSE37405), which contains miRNA expres-
sion data of ER-positive breast cancer patients treated with adjuvant tamoxifen. Kaplan–Meier analysis 
of recurrence-free survival was performed using a statistical software package EZR (Saitama Medical 
Center, Jichi Medical University, Saitama, Japan)65.
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